10.85
0.15 (1.40%)
| Penutupan Terdahulu | 10.70 |
| Buka | 10.59 |
| Jumlah Dagangan | 579,045 |
| Purata Dagangan (3B) | 1,234,793 |
| Modal Pasaran | 1,746,719,872 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.49 |
| Harga / Jualan (P/S) | 4.60 |
| Harga / Buku (P/B) | 1.64 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -8.34% |
| Margin Operasi (TTM) | 6.74% |
| EPS Cair (TTM) | -0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 29.53% |
| Nisbah Semasa (MRQ) | 2.86 |
| Aliran Tunai Operasi (OCF TTM) | 54.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 70.56 M |
| Pulangan Atas Aset (ROA TTM) | 0.59% |
| Pulangan Atas Ekuiti (ROE TTM) | -2.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Bercampur | Menurun |
| Health Information Services (Global) | Bercampur | Menurun | |
| Stok | Certara, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.59% |
| % Dimiliki oleh Institusi | 95.94% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 16.00 (UBS, 47.47%) | Beli |
| Median | 13.00 (19.82%) | |
| Rendah | 12.00 (Barclays, 10.60%) | Pegang |
| Purata | 13.67 (25.99%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 11.02 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 07 Nov 2024 | 12.00 (10.60%) | Pegang | 10.99 |
| 15 Oct 2024 | 14.00 (29.03%) | Pegang | 11.21 | |
| Baird | 05 Nov 2024 | 13.00 (19.82%) | Pegang | 10.31 |
| UBS | 27 Sep 2024 | 16.00 (47.47%) | Beli | 11.75 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Dec 2024 | Pengumuman | Certara Showcases 2024 Research Wins With Over 100 Papers Published |
| 06 Nov 2024 | Pengumuman | Certara Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | Pengumuman | Certara to Participate in the Stephens Annual Investment Conference |
| 16 Oct 2024 | Pengumuman | Certara Appoints John Reynders as New Independent Board Member |
| 09 Oct 2024 | Pengumuman | Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 |
| 02 Oct 2024 | Pengumuman | Certara Completes Acquisition of Chemaxon |
| 02 Oct 2024 | Pengumuman | Certara Completes Acquisition of Chemaxon |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |